What is the phase 3 SUCCESSOR-2 trial?
Dr. Dimopoulos reviews the clinical efficacy of adding the novel cereblon E3 ligase modulator (CELMoD), mezigdomide, to carfilzomib and dexamethasone (MeziKd) for patients
Focus on CELMoDs
EHA 2026
Meetings / Conferences
Multiple Myeloma
Roundtable Discussions
Video Interviews
Past Sessions
Community Oncology
Cellular Therapy
Multiple Myeloma
News
Video Interviews
Dr. Jeffery Matous presents ‘Managing access to novel agents in the community setting’
The third session of the Community Oncology Brown Bag Series, hosted by SOHO Insider, held on March 18, 2026, and featured guest speaker
Lymphoma
Mantle Cell Lymphoma
News
China NMPA grants accelerated approval to rocbrutinib in relapsed or refractory mantle cell lymphoma
The NMPA approval was based on data from the phase 2 ROCK-1 study evaluating rocbrutinib monotherapy in patients with MCL who had relapsed
Lymphoma
Aggressive B-Cell Lymphomas
News
Tafasitamab combo approved in Japan for relapsed, refractory DLBCL
The clinical approval was based on data from the international phase 2 L-MIND trial and the domestic phase 1b/2 J-MIND trial in Japan.
Myeloproliferative Neoplasms
Polycythemia Vera
Taiwan regulatory body approves ropeginterferon alfa-2b-njft in ET
Taiwan’s Ministry of Health and Welfare has approved ropeginterferon alfa-2b-njft (BESREMi) for adult patients with essential thrombocythemia, according to PharmaEssentia, the manufacturer of
Multiple Myeloma
News
CHMP recommends approval of isatuximab subcutaneous formulation for MM
The recommendation was based on results from the phase 3 IRAKLIA trial, which demonstrated that the subcutaneous formulation was noninferior to intravenous administration
AACR 2026
Acute Myeloid Leukemia
Myelodysplastic Syndromes
News
Video Interviews
John DiPersio, MD, PhD, on the future of blood cancers
In this SOHO Insider interview from the 2026 AACR Annual Meeting, John DiPersio, MD, PhD, president of the Society of Hematologic Oncology, shares
Multiple Myeloma
News
Singapore’s HSA approves NDA for CAR-T therapy eque-cel in relapsed or refractory myeloma
Eque-cel, an anti-BCMA CAR-T, has been approved in China for treating patients with relapsed or refractory myeloma who have progressed after at least
SOHO 2026
Meetings / Conferences
News
Society Updates
Grab your SOHO t-shirts during SOHO 2026!
Your contributions fund vital programs that accelerate progress in hematologic malignancies. Visit soho.click/donate to join the initiative.
![Insider_YT_Feature_Pannunzio_CLFR2_400x400[15]](https://sohoinsider.com/wp-content/uploads/2026/06/Insider_YT_Feature_Pannunzio_CLFR2_400x40015.png)
AACR 2026
Acute Lymphoblastic Leukemia
News
Video Interviews
Nicholas Pannunzio, PhD, discusses Ph-like ALL and CRLF2 rearrangement
Nicholas R. Pannunzio, PhD, of the Chao Family Comprehensive Cancer Center, discusses the underlying etiology of CRLF2-rearranged Ph-like acute lymphoblastic leukemia.